Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 1, 2013, Pages 87-94

  Moes, Johannes ^a   Koolen, Stijn ^a,b   Huitema, Alwin ^a,b   Schellens, Jan ^b,c   Beijnen, Jos ^a,b,c   Nuijen, Bastiaan ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Low dose metronomic chemotherapy; Oral chemotherapy; Oral paclitaxel; PVP; Ritonavir; Ternary solid dispersion

Indexed keywords

DODECYL SULFATE SODIUM; PACLITAXEL; POVIDONE; RITONAVIR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MALE; METRONOMIC DRUG ADMINISTRATION; ORAL SOLID DISPERSION; X RAY DIFFRACTION;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PERMEABILITY; POVIDONE; SODIUM DODECYL SULFATE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84871922562     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.09.016     Document Type: Article

References (51)

1. J. Wang, P. Lou, R. Lesniewski, and J. Henkin Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly Anticancer Drugs 14 2003 13 19
2. J.R. Merchan, D.R. Jayaram, J.G. Supko, X. He, G.J. Bubley, and V.P. Sukhatme Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition Int. J. Cancer 113 2005 490 498
3. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat. Rev. Cancer 4 2004 423 436
4. M. Zhang, W. Tao, S. Pan, X. Sun, and H. Jiang Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts Anticancer Drugs 20 2009 355 363
5. R.S. Bhatt, J. Merchan, R. Parker, H. Wu, L. Zhang, V. Seery, J.V. Heymach, M.B. Atkins, D. McDermott, and V.P. Sukhatme A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma Cancer 116 2010 1751 1756
6. R.T. Liggins, W.L. Hunter, and H.M. Burt Solid-state characterization of paclitaxel J. Pharm. Sci. 86 1997 1458 1463
7. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
8. J.M. Meerum Terwogt, J.H. Beijnen, W.W. Ten Bokkel Huinink, H. Rosing, and J.H. Schellens Co-administration of cyclosporin enables oral therapy with paclitaxel Lancet 352 1998 285
9. S.L.W. Koolen, A.D.R. Huitema, B. Thijssen, J.J. Hendrikx, H. Rosing, S. Marchetti, M. Keessen, J.H. Beijnen, J.H.M. Schellens, 3.1 Paclitaxel can be administered orally in combination with CYP3A4 inhibitors as pharmacokinetic boosters, in: S.L.W. Koolen (Ed.), Intravenous-to-Oral Switch in Anticancer Chemotherapy: Focus on Taxanes and Gemcitabine, 1st ed., University of Utrecht, Enschede, 2011, p. 105.
10. Abbott Laboratories Ltd., European Medicines Agency, Norvir (r) summary of product characteristics EMA.
11. W.L. Chiou, and S. Riegelman Pharmaceutical applications of solid dispersion systems J. Pharm. Sci. 60 1971 1281 1302
12. S. Janssens, and G. van den Mooter Review: physical chemistry of solid dispersions J. Pharm. Pharmacol. 61 2009 1571 1586
13. A.K. Aggarwal, and S. Singh Physicochemical characterization and dissolution study of solid dispersions of diacerein with polyethylene glycol 6000 Drug Dev. Ind. Pharm. 37 2011 1181 1191
14. Y. Kawabata, Y. Aoki, T. Matsui, K. Yamamoto, H. Sato, S. Onoue, and S. Yamada Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats Eur. J. Pharm. Biopharm. 77 2011 178 181
15. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
16. D.Q. Craig The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 2002 131 144
17. P. Srinarong, J.H. Faber, M.R. Visser, W.L. Hinrichs, and H.W. Frijlink Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants Eur. J. Pharm. Biopharm. 73 2009 154 161
18. A.T. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
19. D.J. van Drooge, W.L. Hinrichs, and H.W. Frijlink Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions J. Control. Release 97 2004 441 452
20. H.R. Guzmán, M. Tawa, Z. Zhang, P. Ratanabanangkoon, P. Shaw, C.R. Gardner, H. Chen, J.P. Moreau, O. Almarsson, and J.F. Remenar Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J. Pharm. Sci. 96 2007 2686 2702
21. D.J. Greenhalgh, A.C. Williams, P. Timmins, and P. York Solubility parameters as predictors of miscibility in solid dispersions J. Pharm. Sci. 88 1999 1182 1190
22. C.M. Hansen Hansen Solubility Parameters a User's Handbook 2007 CRC Press Boca Raton
23. J.H. Hildebrand, and R.L. Scott The Solubility of Non-Electrolytes 1950 Reinhold Publishing Corporation New York
24. J.J. Moes, S.L.W. Koolen, A.D.R. Huitema, J.H.M. Schellens, J.H. Beijnen, and B. Nuijen Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001) Int. J. Pharm. 420 2011 244 250
25. S.C. van der Schoot, B. Nuijen, F.M. Flesch, A. Gore, D. Mirejovsky, L. Lenaz, and J.H. Beijnen Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle AAPS PharmSciTech 8 2007 E61
26. EDQM, Dissolution tests for solid dosage forms, in: Dissolution Tests for Solid Dosage Forms European Pharmacopoeia, 2011.
27. United States Pharmacopeia Convention, Dissolution, in: United States Pharmacopeia Convention (Ed.), United States Pharmacopeia and National Formulary, USP 34-NF 29 ed.
28. M.T. Huizing, H. Rosing, F. Koopman, A.C. Keung, H.M. Pinedo, and J.H. Beijnen High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 664 1995 373 382
29. T.G. Fox Influence of diluent and of copolymer composition on the glass temperature of a polymer system Bull. Am. Phys. Soc. 1 1956 123
30. L.D. Vainchtein, B. Thijssen, E. Stokvis, H. Rosing, J.H. Schellens, and J.H. Beijnen A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry Biomed. Chromatogr.: BMC 20 2006 139 148
31. R Development Core Team, R: A Language and Environment for Statistical, Computing, 2009.
32. A.N. Ghebremeskel, C. Vemavarapu, and M. Lodaya Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability Int. J. Pharm. 328 2007 119 129
33. L. Lindfors, S. Forssén, J. Westergren, and U. Olsson Nucleation and crystal growth in supersaturated solutions of a model drug J. Colloid Interface Sci. 325 2008 404 413
34. K.A. Overhoff, J.T. McConville, W. Yang, K.P. Johnston, J.I. Peters, and R.O. Williams Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing Pharm. Res. 25 2008 167 175
35. J.M. Meerum Terwogt, M.M. Malingre, J.H. Beijnen, W.W. ten Bokkel Huinink, H. Rosing, F.J. Koopman, O. van Tellingen, M. Swart, and J.H. Schellens Coadministration of oral cyclosporin A enables oral therapy with paclitaxel Clin. Cancer Res. 5 1999 3379 3384
36. M.M. Malingre, D.J. Richel, J.H. Beijnen, H. Rosing, F.J. Koopman, W.W. Ten Bokkel Huinink, M.E. Schot, and J.H. Schellens Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel J. Clin. Oncol. 19 2001 1160 1166
37. L. Gianni, C.M. Kearns, A. Giani, G. Capri, L. Vigano, A. Lacatelli, G. Bonadonna, and M.J. Egorin Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J. Clin. Oncol. 13 1995 180 190
38. S.S. Ng, W.D. Figg, and A. Sparreboom Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins Cancer Res. 64 2004 821 824
39. S.S. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W.D. Figg, and R.S. Kerbel Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel Clin. Cancer Res. 12 2006 4331 4338
40. C.M. Kruijtzer, J.H. Schellens, J. Mezger, M.E. Scheulen, U. Keilholz, J.H. Beijnen, H. Rosing, R.A. Mathôt, S.G. Marcus, H. van Tinteren, and P. Baas Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 20 2002 4508 4516
41. C.M. Kruijtzer, H. Boot, J.H. Beijnen, H.L. Lochs, F.X. Parnis, A.S. Planting, J.M. Pelgrims, R. Williams, R.A. Mathôt, H. Rosing, M.E. Schot, H. Van Tinteren, and J.H. Schellens Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer Ann. Oncol. 14 2003 197 204
42. H.H. Helgason, C.M. Kruijtzer, A.D. Huitema, S.G. Marcus, W.W. Ten Bokkel Huinink, M.E. Schot, J.H. Schornagel, J.H. Beijnen, and J.H. Schellens Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer Br. J. Cancer 95 2006 794 800
43. S.A. Veltkamp, B. Thijsen, J.S. Garrigue, G. Lambert, F. Lallemand, F. Binlich, A.D. Huitema, B. Nuijen, A. Nol, J.H. Beijnen, and J.H. Schellens A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer Br. J. Cancer 95 2006 729 734
44. S.A. Veltkamp, C. Alderden-Los, A. Sharma, H. Rosing, J.H. Beijnen, and J.H. Schellens A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application Cancer Chemother. Pharmacol. 59 2007 43 50
45. E.I. Heath, P. Lorusso, S.S. Ramalingam, A. Awada, M.J. Egorin, T. Besse-Hamer, F. Cardoso, M. Valdivieso, T. Has, L. Alland, X. Zhou, and C.P. Belani A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies Invest. New Drugs 29 2011 1426 1431
46. M.I. Nicoletti, T. Colombo, C. Rossi, C. Monardo, S. Stura, M. Zucchetti, A. Riva, P. Morazzoni, M.B. Donati, E. Bombardelli, M. D'Incalci, and R. Giavazzi IDN5109, a taxane with oral bioavailability and potent antitumor activity Cancer Res. 60 2000 842 846
47. L. Barboni, R. Ballini, G. Giarlo, G. Appendino, G. Fontana, and E. Bombardelli Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390 Bioorg. Med. Chem. Lett. 15 2005 5182 5186
48. R.K. Ramanathan, J. Picus, H. Raftopoulos, S. Bernard, A.C. Lockhart, G. Frenette, J. Macdonald, S. Melin, D. Berg, F. Brescia, H. Hochster, and A. Cohn A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer Cancer Chemother. Pharmacol. 61 2008 453 458
49. Z. Chu, J.S. Chen, C.T. Liau, H.M. Wang, Y.C. Lin, M.H. Yang, P.M. Chen, E.R. Gardner, W.D. Figg, and A. Sparreboom Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients Anticancer Drugs 19 2008 275 281
50. Y.S. Hong, K.P. Kim, H.S. Lim, K.S. Bae, M.H. Ryu, J.L. Lee, H.M. Chang, Y.K. Kang, H. Kim, T.W. Kim, A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel, Invest. New Drugs (2012).
51. M. Siewert, J. Dressman, C.K. Brown, and V.P. Shah FIP, AAPS, FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms AAPS PharmSciTech 4 2003 E7